Introduction: Diabetes mellitus is the most common endocrine illness, affecting over 100 million individuals globally (6% of the population). Methods: A prospective open-label study was conducted from November 2021 to June 2022 at Baquba Teaching Hospital/ Diyala., In current study, 50 patients (23 males and 27 females) had type 2 Diabetic from 2 to 4 years and they were obese, hypertensive and dyslipidemic. They received liraglutide for 12 weeks as 0.6 mg/day. Patients underwent measurements for fasting glucose level, lipid profile, glycosylated hemoglobin and their liver function before and after 12 weeks of treatment. Results: The results of current study revealed that treatment with liraglutide for 12 weeks showed significant beneficial effects on fasting glucose level, lipid profile and glycosylated hemoglobin (P<0.05) but without adversely affecting liver function (P>0.05). Conclusion: In obese type 2 diabetic patients, liraglutide can exert beneficial effects on glycemic control and lipid profile but without producing adverse effects on liver functions. Keywords: